An evidence-based systematic review of active hexose correlated compound (AHCC) by the natural standard research collaboration

Journal of Dietary Supplements

Volumn 10, Issue 3, 2013, Pages 264-308

  Ulbricht, Catherine ^a   Brigham, Ashley ^b   Bryan, J Kathryn ^a   Catapang, Marisa ^a   Chowdary, Divya ^c   Costa, Dawn ^a   Culwell, Samantha ^a   D'Auria, Denise ^b   Giese, Nicole ^a   Iovin, Ramon ^a   Isaac, Richard ^a   Juturu, Vijaya ^a   Liu, Angela ^a   Mintzer, Meredith ^a   Rusie, Erica ^a   Shaffer, Michael ^d   Windsor, Regina C ^a  

^a Natural Standard   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c California Northstate College of Pharmacy   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Active hexose correlated compound; Adverse effects; AHCC; Dosing; Evidence based; Interactions; Pharmacodynamics; Pharmacokinetics; Pharmacology; Systematic review

Indexed keywords

EID: 84883041874     PISSN: 19390211     EISSN: 1939022X     Source Type: Journal    
DOI: 10.3109/19390211.2013.822631     Document Type: Article

References (125)

1. Amenomori S, Fukatsu K, Murakoshi S, Yanagawa M, Mitsui T, Yokota H, Yashuhara H. Does AHCC supplementation prevent 5-FU-induced impairment of gut immunity? A pilot animal study. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
2. Aviles H, Belay T, Fountain K, Vance M, Sun B, Sonnenfeld G. Active hexose correlated compound enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimbunloading model of spaceflight conditions. J Appl Physiol. 2003;95(2):491-496.
3. AvilesH, Belay T, VanceM, Sun B, Sonnenfeld, G.Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions. J Appl.Physiol. 2004;97(4):1437-1444.
4. Aviles H, O'Donnell P, Orshal J, Fujii H, Sun B, Sonnenfeld, G. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg. 2008;195(4):537-545.
5. Aviles H, O'Donnell P, Sun B, Sonnenfeld, G. Active hexose correlated compound (AHCC) enhances resistance to infection in a mouse model of surgical wound infection. Surg Infect (Larchmt). 2006;7(6):527-535.
6. Bach A, Ferrer A, Puig DM, Ahedo J, Chetri, C. Effects of supplementing a combination of nucleoforceR-andAHCC to dairy calves prior weaning on respiratory afflictions and immune response during the postweaning period. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
7. Badawi TA, Khalil NA, Abdelrahman AH, Aly ZH. Immunoprophylactic effect of active hexose correlated compound on normal and induced submandibular salivary gland neoplasm in Albino rats. Presented at the 20th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2012.
8. Bold-Erdene A, Baatamum A, Jigjidsuren, C. Efficacy of active hexose correlated compound (AHCC) in treatment of hepatocellular carcinoma patients at the National Cancer Center of Mongolia. Presented at the 20th InternationalCongress on Nutrition and IntegrativeMedicine (ICNIM) 2012.
9. Burikhanov RB, Wakame K, Igarashi Y, Wang S, Matsuzaki, S. Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat. Endocr Regul. 2000;34(4):181-188.
10. Cao Z, Lin W, Chen R, Chen X, Liao L, Ou, J. The preliminary study of AHCC freeze-dried powder and AHCC serum on proliferation and apoptosis of hepatoma cell line. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
11. Cheadle WG, Peyton J, Aviles H, Sonnenfeld, G. The effect of active hexose correlated compound (AHCC) on the innate host immune response to chronic murine peritonitis. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
12. Chutaputthi, A. Pilot study ofAHCCon HBeAgLevel inCHBeAgpositive patients on long term anti-viral treatment. Presented at the 20th InternationalCongress on Nutrition and Integrative Medicine (ICNIM) 2012.
13. Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa, W. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol. 2006;24(1):33-45.
14. Daddaoua A, Martinez-PlataE, Lopez-PosadasR, Vieites JM, Gonzalez M, Requena P, Zarzuelo A, Suarez MD, de Medina FS, Martinez-Augustin, O. Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr. 2007;137(5):1222-1228.
15. Daddaoua A, Martinez-Plata E, Ortega-Gonzalez M, Ocon B, Aranda CJ, Zarzuelo A, Suarez MD, de Medina FS, Martinez-Augustin, O. The nutritional supplement active hexose correlated compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF-kappaB/MAPK activation. Food Chem. 2013;136(3-4):1288-1295.
16. Drannik AG, Kurchenko AI, Savchenko VS, Drannik GN. AHCC induces in vitro functional activity ofPBMC-derived mononuclear cells from subjects with recurring herpes simplex type 1 and 2 infections. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
17. Du, J. Effect of AHCC for peripheral blood VEGF in hepatocarcinoma- inoculated mice. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
18. Du, J. Anti-tumor Effects of AHCC in H22 tumor-bearing ICR mice and BALB/c nude mice. Presented at the 19th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2011.
19. Fujii H, Nishioka H, Wakame K, Sun, B. Nutritional food active hexose correlated xompound (AHCC) enhances resistance against bird flu. Jpn J Complimentary and Alt Med. 2007;4(2):37-39.
20. Fujii H, Nishioka N, Simon RR, Kaur R, Lynch B, Roberts, A. Genotoxicity and subchronic toxicity evaluation of active hexose correlated compound (AHCC).Regul Toxicol Pharmacol. 2011;59(2):237-250.
21. Fuller R, Kenyon J. A review of AHCC and 1-3/1-613 glucan on natural killer cell activity in a series of cancer patients. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
22. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. 2006;55(10):1258-1266.
23. Garcia JJ, Bautista L, Bolas F, Fujii H, Torrado-Duran JJ. Effect of AHCC on the anthelmintic activity of Albendazole. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
24. Gardner E. AHCC supplementation of energy-restricted mice may improve natural killer cell function during primary influenza infection. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
25. Ghoneum M, Wimbley M, Salem F, McKlain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hexose correlated compound (AHCC). Int J Immunother. 1995;11:23-28.
26. Ghonewn M. NK-immunomodulation by active hemicellulose compound (AHCC) in 17 cancer patients. Presented at the 2nd Meeting of the Society for Natural Immunity 1994.
27. Haidari M, Zhang W, Chen, Z. Active hexose correlated compound (AHCC) inhibits disruption of endothelial adherens junction induced by high concentration of glucose. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
28. Haidari M, Zhang W, Chen Z, Ganjehei L, Mortazavi A, Dixon R. AHCC attenuates cytokineinduced attachment of invasive cancer cells to endothelial cells. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011a.
29. Haidari M, ZhangW, Chen Z, Ganjehei L, Mortazavi A, andDixon, R.AHCCprotects endothelial cells against disruption of adherens junction by pro-inflammatory stimuli [general lecture]. Presented at the 19th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2011b.
30. Hangai S, Yamaguchi T, Kuroda Y, Kogure Y, Iwase S. Exploratory clinical research on active hexose correlated compound (AHCC): effect ofAHCC on patients with breast cancer treated with adjuvant chemotherapy. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
31. HayamaK, YamazakiM, Abe, S. Protective activity of combination ofAHCCandUREXagainst murine vaginal candidiasis. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
32. Hirata S, Takanari J, Wakame, K. Evaluation of AHCC for quality of life (QOL) as integrative medicine during treatment of advanced head and neck cancer patients. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
33. Hirooka S, Yanagimoto H, Satoi S, Toyokawa H, Yamamoto T, Yui R, Yamaki S, Michiura T, Inoue K, Kwon, A. Effect of administration of AHCC in rat with subcutaneous tumor of pancreatic cancer cell. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
34. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, and Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222(2):152-158.
35. Hisajima T, Maruyama N, Funakoshi K, Abe, S. Effect of AHCC on the mucosal immune system of the mice with intestinal candidiasis. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
36. Hong SJ, Chung BH, Kim JS, Lee MJ, Yoon S, Oh HY, Lee EJ, Lim HG, Buxiang, S. The effects of GAC on the biochemical profiles and quality of life of metastatic prostate cancer patients. Korean J Urol. 2006;47(5):467-474.
37. Hunter RJ, Fujii H, Wakame K, GaikwadA, Wolf JK, Smith JA. Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod. 2011;4(3):6-14.
38. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin.Oncol. 2005;23(12):2645-2654.
39. Ikeda T, Ishibashi H, Fujisaki R, Yamazaki M, Wakame K, Kosuna K, Yamaguchi H, Ono Y, Abe S. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal Candida albicans infection in experimental granulocytopenic mice]. Nihon Ishinkin Gakkai Zasshi. 2003;44(2):127-131.
40. Ishibashi H, Ikeda T, Tansho S, Ono Y, Yamazaki M, Sato A, Yamaoka K, Yamaguchi H, Abe S. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal opportunistic infections in mice]. Yakugaku Zasshi. 2000;120(8):715-719.
41. Ishizuka R, FujiiH, Miura T, Fukuchi Y, Tajima K. Therapeutic gaps between the evidence based medicine (EBM) and cancer patients in the advanced stage or recurrence: review of cancer therapy with AHCC and GCP under individual EBMfrom the long-term follow-up over 11 years for cancer of the lung and the Brea. Presented at the 17th International Congress on Nutrition and Integrative Medicine (ICNIM) 2009.
42. Ishizuka R, Fujii H, Miura T, Fukuchi Y, Tajima K. Review of cancer therapy with AHCCR-and GCPR-; The long-term follow-up over 12 years for stage IV (M1) cancer of the lung and the breast. Int J Integr Med. 2010;2(1):98-111.
43. Ishizuka R, Fujii H, Miura T, Fukuchi Y, Tajima K. Personalized cancer therapy with AHCC and GCP; The long-term follow-up over 16 years for stage IV (Ml) of non-small cell lung cancer (NSCLC). Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
44. Iwamoto M. Effects of AHCC on diabetes by clinical and basic researches. The 2nd Annual Meeting of the Japanese Society for Alternative Medicine & Treatment 1999.
45. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials. 1996;17(1):1-12.
46. Jiang S, Nakano T, Nishizawa M, Kimura T. Effect of AHCC on IFN-al antisense RNA and mRNA expression levels in the respiratory tract of influenza virus AlPR/8/34-infected guinea pigs. Presented at the 20th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2012.
47. Karkow A, Karkow F. AHCC: a personal experience. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
48. KawaguchiY. Improved survival of patients with gastric cancer or colon cancerwhen treated with active hexose correlated compound (AHCC): effect ofAHCCon digestive system cancer. Nat Med J. 2009;1(1):1-6.
49. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment.AlternMed Rev. 2000;5(1):4-27.
50. Kim J. The effect of AHCC in non-viral, chronic and abnormal liver function condition: a randomized, double-blind, placebo-control study. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
51. Kulkarni, A. Dietary AHCC in acute gut injury model. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
52. Kulkarni A, Malya RR, Karkow F. Targeted immunonutrition for chronic non-communicable diseases (NCDs) in resource limited settings. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
53. Kurokawa, T. Use of AHCC in multimodality therapy against advanced or terminal cancer. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
54. Lee WW, Kang I. Investigating the effect of AHCC and a-glucan on IL-IP and IL-6 production from human monocytes. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
55. Lee WW, Lee N, Fujii H, Kang, I. Active hexose correlated compound promotes T helper (Th) 17 and 1 cell responses via inducing IL-1beta production from monocytes in humans. Cell Immunol. 2012;275(1-2):19-23.
56. Lee WW, Shin MS, Kang, I. AHCC induces production ofIL-17 from CD4+ T cells via stimulating monocytes in humans. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
57. Luo A, Zhang K, Wakame K, Kulkarni, A. Dietary active hexose correlated compound (AHCC) decreases ischemial reperfusion injury [general lecture]. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
58. Mach CM, Fugii H, Wakame K, Smith J. Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr Oncol. 2008;6(3):105-109.
59. Maeno H, Takanari J, Wakame K. Effect of AHCC for palliative care in horne care patients with terminal cancer. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
60. Masuyama T, Mizuishi Y, Moriyama A, Takeshita K, Takahashi T, Kuwabara M. Application of new immunotherapy using AHCC for animal disease. Presented at the 8th International Congress on Nutrition and Integrative Medicine (ICNIM) 2000.
61. Matsui K, Kawaguchi Y, Ozaki T, Tokuhara K, Tanaka H, Kaibori M, Matsui Y, Kamiyama Y, Wakame K, Miura T, Nishizawa M, Okumura, T. Effect of active hexose correlated compound on the production of nitric oxide in hepatocytes. JPEN J Parenter Enteral Nutr. 2007;31(5):373-380.
62. Matsui K, Ozaki T, Oishi M, Tanaka Y, KaiboriM, Nishizawa M, Okumura T, Kwon AH. Active hexose correlated compound inhibits the expression of proinflammatory biomarker iNOS in hepatocytes. Eur Surg Res. 2011;47(4):274-283.
63. Matsui Y, KamiyamaY.Retrospective study in breast cancer patients supplementedwithAHCC. Int J Integr Oncol. 2009;3(2):12-16.
64. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37(1):78-86.
65. Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li YQ, Hosokawa, M. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs. 1998;9(4):343-350.
66. Matuo A, Yamada M, Nakayama K, Sudou K, Yamada K, Nakagawa H, Takahasi T, Takeshita K, Kuwabara M. Application of the new immunotherapy using AHCC for animal disease I. Presented at the 8th International Congress on Nutrition and Integrative Medicine (ICNIM) 2000.
67. Miyaji T, Hangai S, Kawaguchi T, Kogure Y, and Yamaguchi T. Exploratory clinical research on active hexose correlated compound in the adjuvant chemotherapy of breast cancer. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
68. Mukoda S, Kosuna K, Okada F.Reduction of side affects of anticancer drugs by active hexose correlated compound (AHCC). Proceedings of the American Association for Cancer Research 1999;40.
69. Nakamoto D, Shigama K, Nishioka H, Fujii H. Alleviating effect of AHCC for gemcitabineinduced hematopoietic toxicity in mice [poster session]. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
70. Nishioka H. Preventive effect of AHCC for avian influenza virus. Presented at the 15th International Symposium of the AHCC Research Association 2007.
71. Nishioka H, Wakame K. Ameliorative effect of AHCC for anticancer drug-induced side effects [general lecture]. Presented at the 16th International Congress on Nutrition and Integrative Medicine (ICNIM) 2008.
72. Nishizawa M, Okuyama T, Yoshigai E, Okumura T. AHCC suppresses expression of cytokine/chemokine mRNA in rat hepatocytes. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
73. Nogusa S, Gerbino J, Ritz BW. Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice. Nutr Res. 2009;29(2):139-143.
74. Nomura T, Adachi S, Ryo H, Kikuya R, Hatanaka E, Tokita Y, Nakajima H, Hongyo T, Parida DK. Prevention of cancer and malformation by active hexose correlated compound (AHCC) in mice and humans. Presented at the 18th InternationalCongress on Nutrition and Integrative Medicine (ICNIM) 2010.
75. Nomura T, Kikuya R, Adachi S, Ryo H, Hatanaka E, Kaji M, Yasuda K, Nakajima H, Hongyo T, Parida DK, Wakame, K. Prevention of cancer and radiation induced disorders by active hexose correlated compound, AHCCin mice and humans. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
76. Nomura T, Nakajima H, Hongyo T, Kikuya R, Adachi S, Ryo H, Tokita Y, Eiko H, Yoshida N, Parida DK, Wakame, K. Inhibition of radiation induced late effects (congenital malformations and leukemia) by active hexose correlated compound, AHCC in mice. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
77. Ocon B, Anzola A, Ortega M, Zarzuelo A, Suarez MD, de Medina FS, and Augustin OM. Active hexose correlated compound and Bifidobacterium longum exert symbiotic effects in experimental colitis. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
78. Ocon B, Anzola A, Ortega-Gonzalez M, Zarzuelo A, Suarez MD, Sanchez de, Medina F, Martinez-Augustin O. Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis. Eur J Nutr. 2013;52(2): 457-466.
79. Okumura T, Matsumyia M, Araki Y, Matsuura T, Kaibori M, Kwon A, Nishioka H, Shigama K, Nakamoto D, Yoshigai E, Hara T, Nishizawa M. Effect of AHCC on the induction of iNOS and proinflammatory cytokines in LPS-treated mice. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
80. Okuyama T, Yoshigai E, Okumura T, Ikeya Y, Nishizawa, M. Parallel assessment of effects of AHCCon longevity of the nematode C. elegans and nitric oxide production in rat hepatocytes. Presented at the 20th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2012.
81. Parida DK, Wakame K, Nomura T. Integrating complimentary and alternative medicine in form of active hexose correlated compound (AHCC) in the management of head & neck cancer patients. Int J Clin Med. 2011;2:588-592.
82. Ritz BW. Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr Rev. 2008;66(9):526-531.
83. Ritz BW, Nogusa S, Ackerman EA, Gardner EM. Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr. 2006;136(11):2868-2873.
84. Roman BE, Beli E, Duriancik DM, Gardner EM. Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine. Nutr Res. 2013;33(1):12-17.
85. Sakaguchi T, Ishizaki M, Kaibori M, Matsui K, Hirooka S, Tsuda T, Matsushima H, Matsui Y, Kwon, A. Complete response of advanced hepatocellular carcinoma using AHCC in multimodality therapy. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
86. Sakaue M, Maeda K, Igura T, Kitagawa T, Sumi R, Hirai K, Kondo K, Ito T. Phase I/II clinical study of AHCC as adverse effect reducer in cancer patients with chemotherapy (the 3rd report). Presented at the 17th AHCC Research Association 2009.
87. Sanchez de Medina F, Plata EM, Romero-Calvo I, Ortega M, Gonzalez R, Daddaoua A, Martinez-Moya P, Zarzuelo A, Suarez MD, Martinez-Augustin O. Correlated compound exerts immunomodulatory effects and induces differentiation in several intestinal cell types that are independent on their prebiotic actions. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
88. Sasaki S, Okawa H, Nishioka H. Activation of macrophages and lymphocytes by AHCCcontaining liquid product. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
89. Sato K, Ohashi S, Tanaka Y, Miki H, Oishi M, Tokuhara K, Kaibori T, Okumura T, Nishizawa M, Kwon A. Occurrence of hydrophilic hepato-protective compounds in AHCC in addition to adenosine. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
90. Shah SK, Walker PA, Moore-Olufemi SD, Sundaresan A, Kulkarni AD, Andrassy RJ. An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient. JPEN J Parenter Enteral Nutr. 2011;35(4):449-458.
91. Shigama K, NakayaA, Wakame K, Nishioka H, Fujii H. Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearingmice. J Exp Ther Oncol. 2009;8(1):43-51.
92. Smith JA, Gaikwad A, Jaffari M, Frumovitz M, Meyer L. Evaluation of active hexose correlated compound (AHCC) for the prevention or delay of tumor growth in human cervical cancer xenograft model. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
93. Smith JA, Hunter RJ, Fujii H, Wakame K, Wolf, J. Defining synergistic activity of the combination of active hexose correlated compound (AHCC) with liposomal doxorubicin (Doxil). Presented at the 18th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2010.
94. Sonnenfeld G. Use of animal models for space flight physiology studies, with special focus on the immune system. Gravit Space Biol Bull. 2005;18(2):31-35.
95. Sonnenfeld G, Peyton J, Cheadle W, Fujii H, and Sun, B. Effects of active hexose correlated compound (AHCC) on stress hormones and immune parameters. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
96. Spierings EL, Fujii H, Sun B, Walshe T. A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. JNutr. SciVitaminol (Tokyo). 2007;53(6):536-539.
97. Sula J. Our experience in measuring the increased activity of Properdin in patients with cancer after using AHCC for six months. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
98. Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, Shinohara N. Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study. Jpn J Clin Oncol. 2010;40(10):967-972.
99. Sun B, Mukoda T, Miura T, Fujii H, Yuan L, White R. Anti-tumor effects of genistein combined polysaccharide (GCP) and active hexose correlated compound (AHCC). Transl Biother. 2001;15(3):379-382.
100. Sun B, Wakame K, Mukoda T, Toyoshima A, Kanazawa T, Kosuna K. Preventive effects of AHCC on carbon tetrachloride induced liver injury in mice. Nat Med. 1997;51(4):310-315.
101. Sun B, Wakame K, Sato E, Nishioka H, Aruoma OI, Fujii H. The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurineand methotrexate-induced liver injury in rodents. Cancer Epidemiol. 2009;33(3-4):293-299.
102. SundaresanA, Wakame K, KulkarniAD. AHCC positively regulates liver metabolism by diminishing oxidative stress and protects the heart by increasing liver trafficking of LDL. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
103. Szalus N. AHCC for treatment of Idiopathic thrombocytopenic purpura in 11 year-old girl-a case report. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
104. Szalus N, Budlewski T. AHCC's impact on the immunological system and adverse effects in patients with disseminated neuroendocrine tumors (NETs) treated with radioisotope preparation (90Y-DOTA-TATE). Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
105. Takahashi T, Shinobu K, Nakayam K, Yamada M, Takeshita K, Yamada K, Kuwabara M. Augmentation of canine cellular immune response by administration of AHCC [general lecture]. Presented at the 8th International Congress on Nutrition and Integrative Medicine (ICNIM) 2000.
106. Tanaka Y, Ohashi S, Sato K, Miki H, Oishi M, Tokuhara K, Kaibori M, Okumura T, Nishizawa M, Kwon AH. Adenosine, a Hepato-protective compound in AHCC. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
107. Terada M, Kitadate K, Nanbo Y, Sato, F. Effects of AHCC on hematological parameters for immunity and stress in thoroughbred horses. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
108. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60(5):643-651.
109. Thaiudom S, Piyaniran W, ChutaputthiA.Astudy of the efficacy of active hexose correlated compound (AHCC) in the treatment of chronic hepatitis C patients at Phramongkutklao Hospital. The Med. News (Thailand). 2010;325:13-16.
110. Tolentino R, Lola C, Santos C, Homma K, de Villa R. AHCC effects in breast cancer prevention, screening, diagnosis and management. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.
111. Turner J, Chaudhary U. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer. Anticancer Drugs. 2009;20(3):215-216.
112. Uno K, Kosuna K, Sun B, Fujii H, Wakame K, Chikumaru S, Hosokawa G, Ueda Y. Active hexose correlated compound (AHCC) improves immunological parameters and performance status of patients with solid tumors. Biotherapy. 2000;14(3):303-309.
113. Urushima H, Matsumoto M, Hayashi N, Maeda K, Tamaki Y, Noguchi S, Ito T. Randomized, placebo-controlled trial (RCT) of AHCC for the reduction of side effects in breast cancer chemotherapy. Presented at the 19th International Congress on Nutrition and Integrative Medicine (ICNIM) 2011.
114. Wakame K. Protective effects of active hexose correlated compound (AHCC) on the onset of diabetes induced by Streptozotocin in the rat. Biomed Res. 1999;20(3):145-152.
115. Waki H, Miyazaki S, Hisajima, T. The effects of AHCC on the autonomic nervous function. Presented at the 20th International Congress on Nutrition and IntegrativeMedicine (ICNIM) 2012.
116. Wang S, Ichimura K, Wakame K. Preventive effects of active hexose correlated compound (AHCC) on oxidative stress induced by ferric nitrilotriacetate in the rat. Dokkyo J Med Sci. 2001a;28(2-3):745-752.
117. Wang S, Wakame K, Igarashi Y, Kosuna K, Matsuzaki S. AHCC on immobilization stress in the rat: beneficial effects of active hexose correlated compound. Dokkyo J Med Sci. 2001b;28(1):559-565.
118. Wang S, Welte T, Fang H, Chang GJ, BornWK, O'Brien RL, Sun B, Fujii H, Kosuna K, Wang T. Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr. 2009;139(3):598-602.
119. Yagami K, Nishizawa M, Shirota T, Shigeru Y, Yagasaki T. AHCC maintains the osteoblastic differentiation of mesenchymal stem cells, inhibiting NO production by the inflammatory cytokines. Presented at the 18th International Congress on Nutrition and Integrative Medicine (ICNIM) 2010.
120. Yagita A, Maruyama S, Wakasugi S, Sukegawa Y. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo. 2002;16(1):49-54.
121. Yanagimoto H, Satoi S, Toyokawa S, Yamamoto T, Hirooka S, Yamao J, Araki H, Matsui Y, Kwon, A. The beneficial effect of active hexose correlated compound (AHCC), a health food component, in patients with pancreatic or biliary tract cancer who underwent chemotherapy. Presented at the 40th APA (American Pancreatic Association) 2009.
122. Ye SF, IchimuraK, WakameK, Ohe M. Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci. 2003;74(5):593-602.
123. Ye SF, Wakame K, Ichimura K, Matsuzaki S. Amelioration by active hexose correlated compound of endocrine disturbances induced by oxidative stress in the rat. Endocr Regul. 2004;38(1):7-13.
124. Yin Z, Fujii H, Walshe T. Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-gamma and/or tumor necrosis factor-alpha in healthy adults. Hum Immunol. 2010;71(12):1187-1190.
125. Zhang XH, Nishioka H, Fujii H. Inhibitory effect of AHCC and GCP on upregulated CD133 and Nestin expressions induced by norepinephrine in C6 glioma cells. Presented at the 20th International Congress on Nutrition and Integrative Medicine (ICNIM) 2012.